Trial
NCT02564796
Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, San Diego
Collaborators
—
Condition
Cyanotic Congenital Heart Disease
Intervention
Epoetin Alfa and Iron
Why stopped
COVID
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-02